Cargando…

Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity

PURPOSE: To investigate 12-month treatment outcomes of anti-vascular endothelial growth factor therapy in eyes with typical exudative age-related macular degeneration with good baseline visual acuity. METHODS: This retrospective observational case series included 18 eyes (18 patients) with typical e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Young Suk, Han, Jung Il, Yoo, Su Jin, Lew, Young Ju, Kim, Jae Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Ophthalmological Society 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239465/ https://www.ncbi.nlm.nih.gov/pubmed/25435749 http://dx.doi.org/10.3341/kjo.2014.28.6.466

Ejemplares similares

Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
por: Kikushima, Wataru, et al.
Publicado: (2021)

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study
por: Sakamoto, Shinichi, et al.
Publicado: (2018)

Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05
por: Koch, Raphael, et al.
Publicado: (2015)

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity
por: Monés, Jordi, et al.
Publicado: (2012)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

Current Smoking Is Associated with a Poor Visual Acuity Improvement after Intravitreal Ranibizumab Therapy in Patients with Exudative Age-Related Macular Degeneration
por: Lee, Sangmoon, et al.
Publicado: (2013)

Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline
por: Minami, Sakiko, et al.
Publicado: (2018)

Visual acuity loss associated with excessive “dry macula” in exudative age-related macular degeneration
por: Takahashi, Hidenori, et al.
Publicado: (2018)

Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone
por: Ruiz-Moreno, José Mª, et al.
Publicado: (2008)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan, Handan, et al.
Publicado: (2014)

Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study
por: Minturn, Robert J., et al.
Publicado: (2021)

Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
por: Davis, R Prince, et al.
Publicado: (2010)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki, Hiroyuki, et al.
Publicado: (2017)

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2017)

Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration
por: Zhang, Xinyuan, et al.
Publicado: (2018)

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration
por: Shaikh, Saad, et al.
Publicado: (2007)

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
por: Nakamura, Tomoko, et al.
Publicado: (2012)

Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes
por: Figurska, Małgorzata, et al.
Publicado: (2011)

Retinal pigment epithelial tear after intravitreal bevacizumab injection for exudative age-related macular degeneration
por: Singh, Sunil Kumar, et al.
Publicado: (2014)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
por: Jeon, Sohee, et al.
Publicado: (2014)

Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor
por: Kim, Kun Hae, et al.
Publicado: (2015)

Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration
por: Shiragami, Chieko, et al.
Publicado: (2017)

The Efficacy of Intravitreal Aflibercept in Submacular Hemorrhage Secondary to Wet Age-related Macular Degeneration
por: Shin, Kyung-Hoon, et al.
Publicado: (2016)

Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab
por: Perdicchi, Andrea, et al.
Publicado: (2015)

Characteristics of the inner retinal layer in the fellow eyes of patients with unilateral exudative age-related macular degeneration
por: Lee, Seong Eun, et al.
Publicado: (2020)

Foveal threshold and photoreceptor integrity for prediction of visual acuity after intravitreal aflibercept on age-related macular degeneration
por: Sakai, Tsutomu, et al.
Publicado: (2018)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up
por: Matsumiya, Wataru, et al.
Publicado: (2013)

Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration
por: Kim, Moosang, et al.
Publicado: (2016)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Matsumiya, Wataru, et al.
Publicado: (2011)

Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
por: Elfandi, Sufian, et al.
Publicado: (2021)

One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis
por: Ono, Aoi, et al.
Publicado: (2018)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
por: Khanani, Arshad M, et al.
Publicado: (2019)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
por: Maggio, Emilia, et al.
Publicado: (2022)

Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degeneration
por: Williams, Gwyn Samuel, et al.
Publicado: (2015)

Effect of Switching Therapy to Pegaptanib in Eyes With the Persistent Cases of Exudative Age-Related Macular Degeneration
por: Shiragami, Chieko, et al.
Publicado: (2014)

The Effect of Ranibizumab on Normal Neurosensory Retina in the Eyes of Patients with Exudative Age Related Macular Degeneration
por: Makri, Olga E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5hvl0vakfimj0chc4nfs2167i8